5AM Partners VI, LLC
5AM Partners VI, LLC's purchase track record
How the stock did after each of 5AM Partners VI, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/11/2025 | CAMP | $4.50M | +116.2% | +93.5% | +1.3% |
| 10/15/2024 | CAMP | $10.00M | -65.2% | -82.8% | -7.2% |
| 7/22/2024 | ARTV | $10.00M | -11.0% | -39.9% | +8.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium. Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Enliven's ENABLE-2 Trial Design Sparks New Questions. Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.
Transaction History
| CAMP | ▲ Buy | Open Market | 2,941,176 | $4.5M | 9/11/2025 | View on chart |
| CAMP | ▼ Sell | Other | 302,770 | — | 10/15/2024 | View on chart |
| CAMP | ▲ Buy | Open Market | 909,090 | $10.0M | 10/15/2024 | View on chart |
| CAMP | ▼ Sell | Other | 1,716,055 | — | 10/15/2024 | View on chart |
| ARTV | ▼ Sell | Other | 1,058,284 | — | 7/22/2024 | View on chart |
| ARTV | ▼ Sell | Other | 112,966 | $1.2M | 7/22/2024 | View on chart |
| ARTV | ▼ Sell | Other | 348,721 | $3.6M | 7/22/2024 | View on chart |
| ARTV | ▲ Buy | Open Market | 833,333 | $10.0M | 7/22/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 688,358 | $10.3M | 2/14/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 136,642 | $2.0M | 2/14/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 417,187 | $6.3M | 1/31/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 82,813 | $1.2M | 1/31/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 164,789 | $2.5M | 9/26/2023 | View on chart |
| ELVN | ▼ Sell | Open Market | 32,711 | $491K | 9/26/2023 | View on chart |
| ELVN | ▼ Sell | Open Market | 367,124 | $5.9M | 8/24/2023 | View on chart |
| ELVN | ▼ Sell | Open Market | 72,876 | $1.2M | 8/24/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial
CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial. CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.